elmiron® tolerability
- Adverse events reported with elmiron® treatment were comparable to those reported under treatment with placebo in regards to quality and quantity1
- The most common adverse events reported in clinical studies are headache, dizziness and gastrointestinal events1
Common (≥1/100 to <1/10) adverse events in SPC:1
| Infections and infestations | Infections, influenza |
| Nervous system disorders | Headache, dizziness |
| Gastrointestinal disorders | Nausea, diarrhoea, dyspepsia, abdominal pain, abdomen enlarged, rectal haemorrhage |
| Skin and subcutaneous tissue disorders | Peripheral oedema, alopecia |
| Musculoskeletal and connective tissue disorders | Back pain |
| Renal and urinary disorders | Urinary frequency |
| General disorders and administration site conditions | Asthenia, pelvic pain |
Should you require more information regarding safety considerations, click here
References
- elmiron® 100 mg hard capsules, Summary of Product Characteristics, Consilient Health Ltd.